Cantor Fitzgerald Maintains Neutral on Amgen, Raises Price Target to $440

Benzinga Newsdesk www.benzinga.com Neutral 54.9%

Neg 0% Neu 54.9% Pos 0%

Cantor Fitzgerald analyst Carter Gould maintains Amgen (NASDAQ:AMGN) with a Neutral and raises the price target from $400 to $440.